Invited Lecture
October, 20（Fri.）14:30 ～ 15:05
Chair		

Room 1（Sonic City Hall 1F LARGE HALL）

Toru Kikuchi（Department of Pediatrics,Saitama Medical University）

The use of technology for achieving Time in Range and Time in Tight range
Tadej Battelino
University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia
KSPE-JSPE Plenary Lecture
October, 20（Fri.）15:10 ～ 15:40
Chair		

Room 1（Sonic City Hall 1F LARGE HALL）

Noriyuki Namba（Division of Pediatrics and Perinatology, Tottori University Faculty ofMedicine）	Molecular and Clinical Characteristics of Monogenic Diabetes in KoreanChildrenChong Kun Cheon
Pusan National University School of Medicine, Yangsan, Korea / Pusan National University
Children’s Hospital, Yangsan, Korea
English Oral Session 1
October 21（Sat.）10:45 ～ 11:25 Room 3（Sonic City Hall 4F INTER NATIONAL CONFERENCE ROOM）
Chairs				Asako Tajima（Division of Endocrinology and Metabolism, Saitama Children’s Medical Center）
Yukihiro Hasegawa（Division of Endocrinology and Metabolism, Tokyo Metropolitan
Children’s Medical Center）

EO1-1	Once-weekly Somapacitan in Japanese Children with GH Deficiency: 2-year
Results from REAL4
Yasuko Fujisawa1, Yasuko Fujisawa1, Jun Mori2, Yasuhisa Ohata3, Yukihito Sato4,
Sebastian Rohrich5, Michael Hojby Rasmussen6, Rikke Beck Bang7, Reiko Horikawa8
1
Dept. of Pediatr., Hamamatsu Univ. Sch. of Med.,
2
Div. of Pediatr. Endo. and Metabolism, Children’s Medical Center, Osaka City General
Hosp.,
3
Dept. of Pediatr., Osaka Univ. Grad. School of Med.,
4
Novo Nordisk Pharma Ltd., Tokyo, Japan,
5
Global Medical Affairs, Rare Endo. Disorders, Novo Nordisk Health Care AG, Zurich,
Switzerland,
6
Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark,7
Novo Nordisk A/S, Aalborg, Denmark,8
Div. of Endo. and Metabolism, Nat. Center for Child Health and Dev.
EO1-2	Model-based analysis of IGF-I response, dosing, and monitoring for onceweekly somapacitan in children with GH deficiency
Jun Mori1, Rasmus Juul Kildemoes2, Yassine Kamal Lyauk2, Joanne C. Blair3, Bradley S. Miller4,
Michael Højby Rasmussen2, Philippe F. Backeljauw5
1
Division of Pediatric Endocrinology and Metabolism, Children’s Medical Center, Osaka City
General Hospital, Osaka, Japan,
2
Novo Nordisk A/S, Søborg, Denmark,3Department of Endocrinology, Alder Hey Children’s NHS Foundation Trust, Liverpool,United Kingdom,
4Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealthFairview Masonic Children’s Hospital, Minneapolis, Minnesota, USA,
5Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine,
Cincinnati, Ohio, USA― 82 ―

English Oral Session 2
October 21（Sat.）11:25 ～ 11:55 Room 3（Sonic City Hall 4F INTER NATIONAL CONFERENCE ROOM）
Chairs				

Kenichi Kashimada（Department of Pediatrics and Developmental Biology, Tokyo Medical andDental University（TMDU））
Eiichiro Satake（Genetics and Epidemiology, Joslin Diabetes Center）

EO2-1	Persistence to growth hormone treatment and clinical characteristics ofpaediatric patients with growth hormone deficiency: A retrospective
database study
Sumito Dateki1, Yukihito Sato2, Jun Mori3
1
Dept. of Pediat., Nagasaki Univ. Graduate School of Biomedical Sciences, Nagasaki, Japan,
2
Novo Nordisk Pharma Ltd., Tokyo, Japan,
3
Division of Pediatric Endocrinology and Metabolism, Children’s Medical Center, Osaka City
General Hospital, Osaka, Japan― 83 ―

Program in English

EO1-3	Patient preference questionnaire response after switching to somapacitan
after taking daily growth hormone: 2-year results from REAL 4
Jun Mori1, Joanne C. Blair2, Bradley S. Miller3, Michael Hojby Rasmussen4, Aristides Maniatis5,Volker Böttcher6, Ho-Seong Kim7, Rikke Beck Bang8, Lasse De Fries Jensen3, Michel Polak9,
Reiko Horikawa10
1
Division of Pediatric Endocrinology and Metabolism, Children’s Medical Center, Osaka City
General Hospital, Osaka, Japan,
2
Department of Endocrinology, Alder Hey Children’s NHS Foundation Trust, Liverpool,United Kingdom,
3
Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth
Fairview Masonic Children’s Hospital, Minneapolis, Minnesota, USA,
4
Novo Nordisk A/S, Søborg, Denmark,5
Rocky Mountain Pediatric Endocrinology, Centennial, CO, USA,
6
Division of Pediatric Endocrinology and Metabolism, MVZ Endokrinologikum Frankfurt
am Main, Frankfurt, Germany,
7
Department of Pediatrics, Severance Children’s Hospital, Institute of Endocrinology, Yonsei
University College of Medicine, Seoul, Republic of Korea,
8
Novo Nordisk A/S, Aalborg, Denmark,9Service d’Endocrinologie, Gynécologie et Diabétologie Pédiatriques, Hôpital Universitaire
Necker Enfants Malades Paris, Assistance Publique-Hôpitaux de Paris, Paris, France,
10Division of Endocrinology and Metabolism, National Center for Child Health andDevelopment, Tokyo, Japan
EO1-4	Effect of Once-Weekly Somatrogon and Once-Daily Somatropin on Body
Mass Index and Metabolic Parameters: Post Hoc Analysis of the Pivotal
Phase 3 Trial
Mohamad Maghnie1, Aristides Maniatis2, Cheri Deal3, Lawrence Silverman4, Monica Nijher5,Michael Wajnrajch6,7, Marc Thomas5, Jose Cara6
1
Clinica Pediatrica, IRCCS Istituto Giannina Gaslini, and DINOGMI, University of Genova,2Rocky Mountain Pediatric Endocrinology, Centennial, CO, USA,
3
Centre de recherche CHU Ste-Justine, Université de Montréal, Montréal, Canada,
4
Goryeb Children’s Hospital, Morristown, NJ, USA,
5
Pfizer Ltd, Tadworth,  UK, 6Pfizer Inc, New York, NY, USA,
7
New York University, Grossman School of Medicine, New York, NY, USAEO2-2	A case of Graves’ disease diagnosed after treatment of idiopathic nephrotic
syndrome in childhood
Chisato Narita1, Naoto Nishizaki2, Noriyuki Takubo3, Naoto Shimura1, Toshiaki Shimizu4
1
Dept. of Pediatr. / Tokyo Rinkai Hosp. ,2
Dept. of Pediatr., Juntendo Univ. Sch. of Med. / Urayasu Hosp. ,3
Dept. of Pediatr., Juntendo Univ. Sch. of Med. / Juntendo Hosp.,
4
Dept. of Pediatr., Juntendo Univ. Grad. Sch. of Med.
EO2-3	Long-term effectiveness and safety of growth hormone therapy in Japanesechildren with short stature due to Noonan syndrome: real-world data.
Koji Muroya1, Masanobu Kawai2, Hiroyuki Yamagishi3, Takaaki Endo4, Alberto Pietropoli5,Reiko Horikawa6
1
Department of Endocrinology and Metabolism, Kanagawa Children’s Medical Center,2
Department of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka
Women’s and Children’s Hospital,
3
Division of Pediatric Cardiology, Department of Pediatrics, Keio University School ofMedicine,
4
Novo Nordisk Pharma Ltd., Medical affairs department,
5
Novo Nordisk Health Care AG,
6
Division of Endocrinology and Metabolism, National Center for Child Health andDevelopment― 84 ―